Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
26 Junio 2023 - 3:01PM
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing
engineered natural killer (NK) cell therapies, today announced that
it will host a conference call on Tuesday, June 27, 2023 at 8:00
a.m. ET to review updated clinical data from the ongoing clinical
trial of NKX101, its allogeneic, off-the-shelf CAR NK cell therapy
candidate engineered to target NKG2D ligands on cancer cells.
Conference Call and WebcastTo access the
conference call, please register through this link:
https://nkx101-clinical-update-conference-call.open-exchange.net/registration
Accompanying slides will also be available on the Investors
section of Nkarta’s website, www.nkartatx.com, and a replay will be
archived on the website for approximately four weeks.
About NKX101NKX101 is an allogeneic,
cryopreserved, off-the-shelf cancer immunotherapy candidate that
uses natural killer (NK) cells derived from the peripheral blood of
healthy donors. It is engineered with a chimeric antigen receptor
(CAR) targeting NKG2D ligands on tumor cells. NKG2D, a key
activating receptor found on naturally occurring NK cells, induces
a cell-killing immune response through the detection of stress
ligands that are widely expressed on cancer cells. NKX101 is also
engineered with a membrane-bound form of interleukin-15 (IL15) for
greater persistence and activity without exogenous cytokine
support. To learn more about the NKX101 clinical trial in adults
with AML or MDS, please visit ClinicalTrials.gov.
About NkartaNkarta is a clinical-stage
biotechnology company advancing the development of allogeneic,
off-the-shelf natural killer (NK) cell therapies. By combining its
cell expansion and cryopreservation platform with proprietary cell
engineering technologies and CRISPR-based genome engineering
capabilities, Nkarta is building a pipeline of future cell
therapies engineered for deep anti-tumor activity and intended for
broad access in the outpatient treatment setting. For more
information, please visit the company’s website at
www.nkartatx.com.
Nkarta Media/Investor Contact:Greg MannNkarta,
Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De May 2023 a May 2024